Note 11 - License, Research and Collaboration Agreements (Details Textual) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended |
|---|---|---|
Nov. 30, 2018 |
Mar. 31, 2026 |
|
| ABL Bio Agreement [Member] | ||
| Upfront Payment | $ 5,000 | |
| Development Milestone Payment | 6,000 | |
| Maximum Development and Regulatory Milestone Payments | 96,000 | |
| ABL Bio Agreement [Member] | Oncology [Member] | ||
| Maximum Commercial Milestone Payments and Royalties | 303,000 | |
| ABL Bio Agreement [Member] | Ophthalmology [Member] | ||
| Maximum Development and Regulatory Milestone Payments | 75,000 | |
| Maximum Commercial Milestone Payments and Royalties | $ 110,000 | |
| Adimab Agreement [Member] | ||
| Milestone Payments Paid | $ 0 | |
| Milestone Payment Obligation | $ 2,000 |